Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 24

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 24
---
 of our intellectual property rights in those jurisdictions.

The laws of some jurisdictions
do not protect intellectual property rights to the same extent as the laws in the United States and the European Union, and many companies
have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our collaboration partners
encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important
for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others
in those jurisdictions.

Some countries in Europe and
China have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many
countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner
may have limited remedies, which could materially diminish the value of such patent. If we are, or any of our licensors is, forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position or commercial advantage
may be impaired and our business and results of operations may be adversely affected.

Changes in patent law could diminish the
value of patents in general, thereby impairing our ability to protect our drug candidates and any future drug candidates.

As is the case with other
biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining
and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and enforcing biopharmaceutical
patents is costly, time-consuming and inherently uncertain. The U. S. Supreme Court in recent years has issued rulings either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations or ruling
that certain subject matter is not eligible for patent protection. In addition to increasing uncertainty with regard to our ability to
obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.
Depending on decisions by Congress, the federal courts, the USPTO and equivalent bodies in non-U. S. jurisdictions, the laws and regulations
governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents
and patents we may obtain in the future.

Patent reform laws, such as
the Leahy-Smith America Invents Act, or the Leahy-Smith Act, as well as changes in how patent laws are interpreted, could increase